Pyruvate secreted from patient‐derived cancer‐associated fibroblasts supports survival of primary lymphoma cells

Cancer‐associated fibroblasts (CAF) are a key component in the tumor microenvironment and play functional roles in tumor metastasis and resistance to chemotherapies. We have previously reported that CAF isolated from lymphoma samples increase anaerobic glycolysis and decrease intracellular production of reactive oxygen species, promoting the survival of tumor cells. Herein, we analyzed the mechanisms underlying this support of tumor‐cell survival by CAF. As direct contact between lymphoma cells and CAF was not indispensable to survival support, we identified that the humoral factor pyruvate was significantly secreted by CAF. Moreover, survival of lymphoma cells was promoted by the presence of pyruvate, and this promotion was canceled by inhibition of monocarboxylate transporters. Metabolome analysis of lymphoma cells in coculture with CAF demonstrated that intermediates in the citric acid cycle were significantly increased, indicating that tumor cells produced energy by aerobic metabolism. These findings indicate that energy production in lymphoma cells is regulated in coordination not only with anaerobic glycolysis, but also with aerobic metabolism termed the reverse‐Warburg effect, involving the secretion of pyruvate from CAF resulting in increased use of the citric acid cycle in lymphoma cells.

[1]  S. Swerdlow WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues , 2017 .

[2]  P. Khong,et al.  PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK/T-cell lymphoma failing l-asparaginase. , 2017, Blood.

[3]  Ya'an Kang,et al.  Cancer-associated fibroblasts enhance pancreatic cancer cell invasion by remodeling the metabolic conversion mechanism , 2017, Oncology reports.

[4]  T. Aoki,et al.  Emetine elicits apoptosis of intractable B-cell lymphoma cells with MYC rearrangement through inhibition of glycolytic metabolism , 2016, Oncotarget.

[5]  T. Funatsu,et al.  Live-cell single-molecule imaging of the cytokine receptor MPL for analysis of dynamic dimerization. , 2016, Journal of molecular cell biology.

[6]  M. Shipp,et al.  Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  T. Naoe,et al.  SPIB is a novel prognostic factor in diffuse large B‐cell lymphoma that mediates apoptosis via the PI3K‐AKT pathway , 2016, Cancer science.

[8]  R. Kalluri The biology and function of fibroblasts in cancer , 2016, Nature Reviews Cancer.

[9]  R. Hill,et al.  CANCER-ASSOCIATED FIBROBLAST EXOSOMES REGULATE SURVIVAL AND PROLIFERATION OF PANCREATIC CANCER CELLS , 2016, Oncogene.

[10]  M. Gasparetto,et al.  Leukemic Stem Cells Evade Chemotherapy by Metabolic Adaptation to an Adipose Tissue Niche. , 2016, Cell stem cell.

[11]  J. Locasale,et al.  The Warburg Effect: How Does it Benefit Cancer Cells? , 2016, Trends in biochemical sciences.

[12]  T. Naoe,et al.  Discovery of a drug targeting microenvironmental support for lymphoma cells by screening using patient-derived xenograft cells , 2015, Scientific Reports.

[13]  L. Solt,et al.  Broad Anti-tumor Activity of a Small Molecule that Selectively Targets the Warburg Effect and Lipogenesis. , 2015, Cancer cell.

[14]  M. Millenson,et al.  PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. , 2015, The New England journal of medicine.

[15]  John M. Asara,et al.  Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function , 2014, Nature.

[16]  R. Gascoyne,et al.  The tumour microenvironment in B cell lymphomas , 2014, Nature Reviews Cancer.

[17]  E. Giannoni,et al.  Reciprocal metabolic reprogramming through lactate shuttle coordinately influences tumor-stroma interplay. , 2012, Cancer research.

[18]  L. Staudt,et al.  Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  T. Naoe,et al.  CML cells expressing the TEL/MDS1/EVI1 fusion are resistant to imatinib-induced apoptosis through inhibition of BAD, but are resensitized with ABT-737. , 2012, Experimental hematology.

[20]  C. Croce,et al.  Stromal control of cystine metabolism promotes cancer cell survival in chronic lymphocytic leukemia , 2012, Nature Cell Biology.

[21]  B. Coiffier,et al.  Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. , 2010, Blood.

[22]  F. Sotgia,et al.  Oxidative stress in cancer associated fibroblasts drives tumor-stroma co-evolution , 2010, Cell cycle.

[23]  S. Barrans,et al.  Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  P. Fortina,et al.  The reverse Warburg effect: Aerobic glycolysis in cancer associated fibroblasts and the tumor stroma , 2009, Cell cycle.

[25]  R. Gascoyne,et al.  MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy. , 2009, Blood.

[26]  R. Gascoyne,et al.  Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival. , 2009, Blood.

[27]  A. López-Guillermo,et al.  CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. , 2006, The Lancet. Oncology.

[28]  T. Hara,et al.  Lymph Node Fibroblastic Reticular Cells Construct the Stromal Reticulum via Contact with Lymphocytes , 2004, The Journal of experimental medicine.

[29]  M. Tomita,et al.  Quantitative metabolome analysis using capillary electrophoresis mass spectrometry. , 2003, Journal of proteome research.

[30]  B. E. C. Oiffier,et al.  CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma , 2002 .

[31]  O. Warburg [Origin of cancer cells]. , 1956, Oncologia.

[32]  Pierre Morel,et al.  CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. , 2002, The New England journal of medicine.

[33]  T. Tlsty,et al.  Carcinoma-associated Fibroblasts Direct Tumor Progression of Initiated Human Prostatic Epithelium , 2022 .